Analiza de situație tbc 2016 Situația tbc la nivel mondial


MDR-TB cases among notified pulmonary TB cases



Yüklə 1 Mb.
səhifə7/21
tarix05.01.2022
ölçüsü1 Mb.
#74828
1   2   3   4   5   6   7   8   9   10   ...   21
MDR-TB cases among notified pulmonary
TB cases


290

(190–430)

360

(270–480)


































TB case notifications 2014

New **

Relapse

Pulmonary, bacteriologically confirmed

7 874

 

1 899

Pulmonary, clinically diagnosed

2 421

 

356

Extrapulmonary

2 209

 

102

 

 

 

 

Total new and relapse

14 861

 

 

Previously treated, excluding relapses

1 045

 

 

Total cases notified

15 906

 

 


































Among 14 861 new and relapse cases:



















639 (4%) cases aged under 15 years; male:female ratio: 2.1





































Reported cases of RR-/MDR-TB 2014

New

Retreatment

Total **

Cases tested for RR-/MDR-TB

5 751 (73%)

2 171 (64%)

7 922

Laboratory-confirmed RR-/MDR-TB cases

 

 

578

Patients started on MDR-TB treatment ***

 

 

648


































TB/HIV 2014

Number

(%)

TB patients with known HIV status

10 927

(69)

HIV-positive TB patients

312

(3)

HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)

281

(90)

HIV-positive TB patients on antiretroviral therapy (ART)

278

(89)

HIV-positive people screened for TB

316

 

HIV-positive people provided with IPT

158

 


































Treatment success rate and cohort size

(%)

Cohort

New and relapse cases registered in 2013

(85)

15 188

Previously treated cases, excluding relapse, registered in 2013

(45)

925

HIV-positive TB cases, all types, registered in 2013

(58)

250

RR-/MDR-TB cases started on second-line treatment in 2012

(34)

638

XDR-TB cases started on second-line treatment in 2012

(7)

41


































Laboratories 2014

 

Smear (per 100 000 population)

0.5

Culture (per 5 million population)

23.2

Drug susceptibility testing (per 5 million population)

11.2

Sites performing Xpert MTB/RIF

3

Is second-line drug susceptibility testing available?

Yes, in country


































Financing TB control 2015

 

National TB programme budget (US$ millions)

18

% Funded domestically

15%

% Funded internationally

67%

% Unfunded

18%


































* Ranges represent uncertainty intervals
















** Includes cases with unknown previous TB treatment history










*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having




RR-/MDR-TB























































***










Yüklə 1 Mb.

Dostları ilə paylaş:

























































































































(Rate per 100 000 population per year)



















































   

Mortality  (excludes HIV+TB)

































































































































































































(Rate per 100 000 population)


































































   

Prevalence








































































































































































































































1   2   3   4   5   6   7   8   9   10   ...   21




Verilənlər bazası müəlliflik hüququ ilə müdafiə olunur ©muhaz.org 2024
rəhbərliyinə müraciət

gir | qeydiyyatdan keç
    Ana səhifə


yükləyin